New diabetes drug candidate TQF3250 enters first human safety trial
NCT ID NCT07327281
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 23 times
Summary
This early-stage trial tests a new capsule called TQF3250 in 66 healthy adults to see if it is safe and how the body handles it. TQF3250 is designed to help control blood sugar by targeting the GLP-1 receptor, a common approach for managing diabetes. The study focuses on side effects and drug levels in the blood, not on treating the disease itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERGLYCEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Drum Tower Hospital Affiliated to Nanjing University School of Medicine
RECRUITINGNanjing, Jiangsu, 210008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.